Cost effectiveness of hepatitis C direct acting agents

References

• Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022;19(8):533–550.
   PubMed Web of Science ®Google Scholar
• Barua S, Greenwald R, Grebely J, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215–223. doi: 10.7326/M15-0406
   PubMed Web of Science ®Google Scholar
• Thomas DL, Longo DL. Global elimination of chronic hepatitis. N Engl J Med. 2019;380(21):2041–2050.
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509–516. doi: 10.1016/j.cgh.2011.03.004
   PubMed Web of Science ®Google Scholar
• Leidner AJ, Chesson HW, Xu F, et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61(6):1860–1869. doi: 10.1002/hep.27736
   PubMed Web of Science ®Google Scholar
• Gordon SC, Pockros PJ, Terrault NA, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CNC) virus infection [published correction appears in hepatology. 2013 Sep;58(3): 1193]. Hepatology. 2012;56(5):1651–1660. doi: 10.1002/hep.25842
   PubMed Web of Science ®Google Scholar
• 2020 viral hepatitis surveillance report. Centers for Disease Control and Prevention. 2022 Aug 18 [cited 2023 Oct 24]. Available from: https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm
   Google Scholar
• Ryerson AB Vital signs: newly reported acute and chronic hepatitis C cases ― United States, 2009–2018. Centers for Disease Control and Prevention. 2023 Mar 17 [cited 2023 Oct 24]. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6914a2.htm#suggestedcitation
   Google Scholar
• Saab S, Le L, Saggi S, et al. Toward the elimination of hepatitis C in the United States. Hepatology. 2018;67(6):2449–2459. doi: 10.1002/hep.29685
   PubMed Web of Science ®Google Scholar
• Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. World Health Organization. 2018 Jul 1 [cited 2023 Oct 24]. Available from: https://www.who.int/publications/i/item/9789241550345
   Google Scholar
• Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332–342. doi: 10.1016/S2468-1253(22)00386-7
   PubMed Web of Science ®Google Scholar
• Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2018;16(8):1356–1358. doi: 10.1016/j.cgh.2017.11.045
   PubMed Web of Science ®Google Scholar
• Jamison DT, Breman JG, Measham AR, et al., editors. Chapter 3, cost-effectiveness analysis. In: Priorities in health. Washington, D.C.: World Bank; 2006. https://www.worldbank.org/en/home
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–1258. doi: 10.1001/jama.1996.03540150055031
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Romano F, Basile M, et al. Cost-effectiveness analysis of early treatment of chronic HCV with Sofosbuvir/Velpatasvir in Italy. Appl Health Econ Health Policy. 2018;16(5):711–722. doi: 10.1007/s40258-018-0410-x
   PubMed Web of Science ®Google Scholar
• Goel A, Chen Q, Chhatwal J, et al. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol. 2018;33(12):2029–2036. doi: 10.1111/jgh.14301
   PubMed Web of Science ®Google Scholar
• Chugh Y, Dhiman RK, Premkumar M, et al. Real-world cost-effectiveness of pan-genotypic sofosbuvir-velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLOS ONE. 2019 [Published 2019 Aug 29];14(8):e0221769. doi: 10.1371/journal.pone.0221769
   PubMed Web of Science ®Google Scholar
• Chan J, Kim JJ, Barrett BK, et al. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021;28(2):260–267. doi: 10.1111/jvh.13419
   PubMed Web of Science ®Google Scholar
• Kawaguchi I, Chayama K, Gonzalez YS, et al. A cost-effectiveness analysis of glecaprevir/pibrentasvir versus existing direct-acting antivilarsto treat chronic hepatitis C in Japan. Adv Ther. 2020;37(1):457–476. doi: 10.1007/s12325-019-01166-3
   PubMed Web of Science ®Google Scholar
• Gordon S, Lee J, Smith N, et al. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020;20(3):251–257. doi: 10.1080/14737167.2019.1629291
   PubMed Web of Science ®Google Scholar
• Chen P, Jin M, Cao Y, et al. Cost-effectiveness analysis of oral direct-acting antivirals for Chinese patients with chronic hepatitis C. Appl Health Econ Health Policy. 2021;19(3):371–387. doi: 10.1007/s40258-020-00623-3
   PubMed Web of Science ®Google Scholar
• Gholamhoseini MT, Sharafi H, Hl BH, et al. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open. 2022 [Published 2022 Jun 8];12(6):e058757. doi: 10.1136/bmjopen-2021-058757
   PubMed Web of Science ®Google Scholar
• Greenhawt M, Oppenheimer J, Codispoti CD. A practical guide to understanding cost-effectiveness analyses. J Allergy Clin Immunol Pract. 2021;9(12):4200–4207. doi: 10.1016/j.jaip.2021.10.006
   PubMed Web of Science ®Google Scholar
• World Health Organization. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. Geneva: WHO; 2022 [cited 2024 Jan 1].https://www.who.int/publications/i/item/9789240052734
   Google Scholar
• Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010 Feb;138:(2):513–521.
   PubMed Web of Science ®Google Scholar
• Jemal A, Fedewa SA. Recent hepatitis C virus testing patterns among baby boomers. Am J Prev Med. 2017 Jul;53(1):e31–e33. doi: 10.1016/j.amepre.2017.01.033
   PubMed Web of Science ®Google Scholar
• US Centers for Disease Control and Prevention. Surveillance Data for Viral Hepatitis. 2021 [cited 2024 Jan 4]. Available from: https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-c.htm
   Google Scholar
• Edlin BR, Eckhardt BJ, Shu MA, et al. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015 Nov;62:(5):1353–1363.
   PubMed Web of Science ®Google Scholar
• Blach S, Terrault NA, Tacke F, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022 May;7:(5):396–415.
   PubMed Web of Science ®Google Scholar
• Tatar M, Keeshin SW, Mailliard M, et al. Cost-effectiveness of universal and targeted hepatitis C virus screening in the United States. JAMA Netw Open. 2020;3(9):e2015756. doi: 10.1001/jamanetworkopen.2020.15756
   PubMed Web of Science ®Google Scholar
• Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis c virus infection in the era of direct-acting, pangenotypic treatment regimens. Clin Gastroenterol Hepatol. 2019 Apr;17(5):930–939.e9. doi: 10.1016/j.cgh.2018.08.080
   PubMed Web of Science ®Google Scholar
• Assoumou SA, Tasillo A, Vellozzi C, et al. Cost-effectiveness and budgetary impact of hepatitis C virus testing, treatment, and linkage to care in US prisons. Clin Infect Dis. 2020 Mar 17;70(7):1388–1396. doi: 10.1093/cid/ciz383
   PubMed Web of Science ®Google Scholar
• Cipriano LE, Zaric GS, Holodniy M, et al. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLOS ONE. 2012;7(9):e45176. doi: 10.1371/journal.pone.0045176
   PubMed Web of Science ®Google Scholar
• Krauth C, Rossol S, Ortsäter G, et al. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. BMC Infect Dis. 2019 Dec 2;19(1):1019. doi: 10.1186/s12879-019-4524-z
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Huneau A, Verleene A, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018 Oct;69:(4):785–792.
   PubMed Web of Science ®Google Scholar
• Gountas I, Sypsa V, Papatheodoridis G, et al. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World J Gastroenterol. 2019 Mar 21;25(11):1327–1340. doi: 10.3748/wjg.v25.i11.1327
   PubMed Web of Science ®Google Scholar
• Global progress report on HIV, viral hepatitis and sexually transmitted infections. World Health Organization. 2021 Jul 15 [cited 2023 Oct 24]. Available from: https://www.who.int/publications/i/item/9789240027077
   Google Scholar
• Hernandez-Con P, Wilson DL, Tang H, et al. Hepatitis C cascade of care in the direct-acting antivirals era: a meta-analysis. Am J Prev Med. 2023 Dec;65:(6):1153–1162.
   PubMed Web of Science ®Google Scholar
• Franco RA, Overton ET, Tamhane AR, et al. Characterizing failure to establish hepatitis C care of baby boomers diagnosed in the emergency department. Open Forum Infect Dis. 2016 Oct 4;3(4):ofw211. doi: 10.1093/ofid/ofw211
   PubMedGoogle Scholar
• Oru E, Trickey A, Shirali R, et al. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob Health. 2021 Apr;9:(4):e431–e445.
   PubMed Web of Science ®Google Scholar
• Kohli A, Shaffer A, Sherman A, et al. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631–640. doi: 10.1001/jama.2014.7085
   PubMed Web of Science ®Google Scholar
• Knox R $1,000 pill for hepatitis C spurs debate over drug prices. Npr. 2013 Dec 30 [cited 2023 Oct 24]. Available from: https://www.npr.org/sections/health-shots/2013/12/30/256885858/-1-000-pill-for-hepatitis-c-spurs-debate-over-drug-prices.
   Google Scholar
• Jung JK, Feldman R, Cheong C, et al. Coverage for hepatitis C drugs in medicare part D. Am J Manag Care. 2016;22(6 Spec No.):SP220–SP226.
   PubMed Web of Science ®Google Scholar
• Ornstein C. The cost of a cure: medicare spent $4.5 billion on new hepatitis C drugs last year. ProPublica. 2015 Mar 30 [cited 2023 Oct 24]. Available from: https://www.propublica.org/article/cost-of-a-cure-medicare-spent-4.5-billion-on-hepatitis-c-drugs-last-year
   Google Scholar
• Robinson JC, Howell S, Pearson SD. Value-based pricing and patient access for specialty drugs. JAMA. 2018;319(21):2169–2170. doi: 10.1001/jama.2018.5367
   PubMed Web of Science ®Google Scholar
• Tice TJ, Ollendorf DA, Chahal HS, et al. The comparative clinical effectiveness and value of novel combination therapies for the treatment of patients with genotype 1 chronic hepatitis C infection. Institute for Clinical and Economic Review. 2015 Jan 30 [cited 2023 Oct 24]. Available from: https://icer.org/wp-conent/uploads/2020/10/Response_to_Public_Coments_013015.pdf
   Google Scholar
• American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2019 [cited 2023 Oct 23]. Available from: https://www.hcvguidelines.org/contents
   Google Scholar
• Mattingly TJ 2nd, Love BL. Changes in cost-effectiveness for chronic hepatitis C virus pharmacotherapy: the case for continuous cost-effectiveness analyses. J Manag Care Spec Pharm. 2020;26(7):879–886. doi: 10.18553/jmcp.2020.26.7.879
   PubMed Web of Science ®Google Scholar
• Bedossa P. Présentation d’une grille d’analyse informatisée pour le recueil des lésions histopathologiques dans l’hépatite chronique virale C. Etude coopérative du groupe METAVIR [Presentation of a grid for computer analysis for compilation of histopathologic lesions in chronic viral hepatitis C. Cooperative study of the METAVIR group]. Ann Pathol. 1993;13(4):260–265.
   PubMedGoogle Scholar
• Scott N, Iser DM, Thompson AJ, et al. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol. 2016 Apr;31:(4):872–882.
   PubMed Web of Science ®Google Scholar
• van Santen DK, de Vos AS, Matser A, et al. Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of Epidemic; extrapolating from Amsterdam, the Netherlands. PLOS ONE. 2016 Oct 6;11(10):e0163488. doi: 10.1371/journal.pone.0163488
   PubMed Web of Science ®Google Scholar
• Scott N, McBryde ES, Thompson A, et al. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut. 2017 Aug;66:(8):1507–1515.
   PubMed Web of Science ®Google Scholar
• Barbosa C, Fraser H, Hoerger TJ, et al. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction. 2019 Dec;114:(12):2267–2278.
   PubMed Web of Science ®Google Scholar
• Stevens ER, Nucifora KA, Hagan H, et al. Cost-effectiveness of direct antiviral agents for hepatitis c virus infection and a combined intervention of syringe access and medication-assisted therapy for opioid use disorders in an injection drug use population. Clin Infect Dis. 2020 Jun 10;70(12):2652–2662. doi: 10.1093/cid/ciz726
   PubMed Web of Science ®Google Scholar
• Marquez LK, Fleiz C, Burgos JL, et al. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. Addiction. 2021 Oct;116:(10):2734–2745.
   PubMed Web of Science ®Google Scholar
• Lim AG, Aas CF, Çağlar ES, et al. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial. Addiction. 2023 Dec;118:(12):2424–2439.
   PubMed Web of Science ®Google Scholar
• Fadnes LT, Aas CF, Vold JH, et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: a multicenter randomized controlled trial (INTRO-HCV). PLOS Med. 2021 Jun 1;18(6):e1003653. doi: 10.1371/journal.pmed.1003653
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Brew IF, et al. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology. 2016 Jun;63:(6):1796–1808.
   PubMed Web of Science ®Google Scholar
• Dalgic OO, Samur S, Spaulding AC, et al. Improved health outcomes from hepatitis c treatment scale-up in spain’s prisons: a cost-effectiveness study. Sci Rep. 2019 Nov 14;9(1):16849. doi: 10.1038/s41598-019-52564-0
   PubMedGoogle Scholar
• Marco A, Domínguez-Hernández R, Casado MA. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain. Rev Esp Sanid Penit. 2020 May;22(2):66–74. doi: 10.18176/resp.00012
   PubMedGoogle Scholar
• Kwon JA, Chambers GM, Luciani F, et al. Hepatitis C treatment strategies in prisons: a cost-effectiveness analysis. PLOS ONE. 2021 Feb 11;16(2):e0245896. doi: 10.1371/journal.pone.0245896
   PubMed Web of Science ®Google Scholar
• Shih STF, Stone J, Martin NK, et al. Scale-up of direct-acting antiviral treatment in prisons is both cost-effective and key to hepatitis C virus elimination. Open Forum Infect Dis. 2023 Dec 18;11(2):ofad637. doi: 10.1093/ofid/ofad637
   PubMed Web of Science ®Google Scholar
• Saab S, Kardashian A, Saggi S, et al. Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective. Clin Transplant. 2018;32(10):e13383. doi: 10.1111/ctr.13383
   PubMed Web of Science ®Google Scholar
• Bethea ED, Samur S, Kanwal F, et al. Cost effectiveness of transplanting HCV-Infected livers into uninfected recipients with preemptive antiviral therapy. Clin Gastroenterol Hepatol. 2019;17(4):739–747. doi: 10.1016/j.cgh.2018.08.042
   PubMed Web of Science ®Google Scholar
• Samur S, Kues B, Ayer T, et al. Cost effectiveness of pre- vs post-liver transplant hepatitis C treatment with direct-acting antivirals. Clin Gastroenterol Hepatol. 2018;16(1):115–122. doi: 10.1016/j.cgh.2017.06.024
   PubMed Web of Science ®Google Scholar
• Cortesi PA, Belli LS, Facchetti R, et al. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: cost-effectiveness analysis of new opportunities. J Viral Hepat. 2018;25(7):791–801. doi: 10.1111/jvh.12877
   PubMed Web of Science ®Google Scholar
• Rockey DC. Fibrosis reversal after hepatitis C virus elimination. Curr Opin Gastroenterol. 2019;35(3):137–144. doi: 10.1097/MOG.0000000000000524
   PubMed Web of Science ®Google Scholar
• Lockart I, Yeo MGH, Hajarizadeh B, et al. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology. 2022;76(1):139–154. doi: 10.1002/hep.32341
   PubMed Web of Science ®Google Scholar
• Yoo HW, Park JY, Kim SG, et al. Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents. Sci Rep. 2022;12(1):193. doi: 10.1038/s41598-021-03272-1
   PubMed Web of Science ®Google Scholar
• Perricone G, Duvoux C, Berenguer M, et al. Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting. Liver Int. 2018;38(12):2170–2177. doi: 10.1111/liv.13878
   PubMed Web of Science ®Google Scholar
• Tsui JI, Lum PJ, Taylor LE, et al. Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs. Drug Alcohol Depend. 2023;247:109878. doi: 10.1016/j.drugalcdep.2023.109878
   PubMed Web of Science ®Google Scholar
• Geist ML, Radick AC, Tsui JI, et al. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study. Addict Sci Clin Pract. 2023;18(1):33. doi: 10.1186/s13722-023-00389-8
   PubMed Web of Science ®Google Scholar